Return to search

Adoptive T cell therapy of breast cancer: defining and circumventing barriers to T cell infiltration in the tumour microenvironment.

In the era of personalized cancer treatment, adoptive T cell therapy (ACT) shows promise for the
treatment of solid cancers. However, partial or mixed responses remain common clinical
outcomes due to the heterogeneity of tumours. Indeed, in many patients it is typical to see a
response to ACT in one tumour nodule, while others show little or no response. Thus, defining
the tumour features that distinguish those that respond to ACT from those that do not would be a
significant advance, allowing clinicians to identify patients that might benefit from this treatment
approach.
The first chapter of this thesis provides the necessary background to understand the principals
behind and components of ACT. This chapter also offers selected historical advances
contributing to the current state of the field. The second chapter introduces a novel murine
model of breast cancer developed to investigate the tumour-specific mechanisms associated
with immune evasion in an ACT setting. The third chapter describes the in vivo characterization
of mammary tumour cell lines derived from our mouse model that reliably showed complete,
partial or no response to ACT. Using these cell lines, we were able to characterize in vivo
tumour-specific differences in cytotoxic T cell trafficking, infiltration, activation, and proliferation
associated with response to ACT. In the fourth chapter, we used bioinformatics approaches to
develop a preliminary predictive gene signature associated with response to ACT in our
mammary tumour model. We used this signature to predict outcome and then test a number of

murine mammary tumours in vivo, with promising results, wherein 50% of tumours responded to
ACT as predicted based upon gene expression. Thus, using an innovative model for breast
cancer, these results suggest that there are tumour-specific features that can be used a priori to
predict how a tumour will respond to adoptive T cell therapy. Importantly, these findings might
facilitate the design of immunotherapy trials for human breast cancer. / Graduate

Identiferoai:union.ndltd.org:uvic.ca/oai:dspace.library.uvic.ca:1828/3655
Date03 November 2011
CreatorsMartin, Michele
ContributorsNelson, Brad H., Koop, Benjamin F.
Source SetsUniversity of Victoria
LanguageEnglish, English
Detected LanguageEnglish
TypeThesis
RightsAvailable to the World Wide Web

Page generated in 0.0023 seconds